Rate limiting barriers for implantable devices

• US 6,896,965 B1
• Filed: 11/12/2002
• Issued: 05/24/2005
• Est. Priority Date: 11/12/2002
• Status: Expired due to Fees

• Current Assignee: Advanced Cardiovascular Systems Incorporated (Abbott Laboratories)
• Original Assignee: Advanced Cardiovascular Systems Incorporated (Abbott Laboratories)
• Inventors: Hossainy, Syed F. A.
• Primary Examiner(s): ZACHARIA, RAMSEY E
• Application Number:
  US10/293,064
• Time in Patent Office: 924 Days
• Field of Search: 623/1.15, 623/1.42, 623/1.44, 623/1.46, 428/36.91, 428/411.1, 428/480, 428/500, 428/522
• US Class Current: 428/411.1
• CPC Class Codes: A61L 27/34 Macromolecular materials
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: Y10T 428/31504 Composite [nonstructural laminate]
• CPC Class Codes: Y10T 428/31786 Of polyester [e.g., alkyd, etc.]
• CPC Class Codes: Y10T 428/31855 Of addition polymer from unsaturated monomers
• CPC Class Codes: Y10T 428/31935 Ester, halide or nitrile of addition polymer

Abstract

A coating for implantable medical devices including an interpenetrating polymer network serving as a rate limiting barrier.

Claims

1. A coating for an implantable medical device comprising a first region and a second region above the first region, wherein the first region comprises a therapeutic substance and the second region comprises an interpenetrating polymer network.

2. The coating of claim 1, wherein the medical device is a stent.

3. The coating of claim 1, wherein a diffusion rate of the therapeutic substance in the second region is less than a diffusion rate of the therapeutic substance in the first region.

4. The coating of claim 1, wherein the therapeutic substance is selected from the group consisting of paclitaxel, docetaxel, rapamycin, 40-O-(2-hydroxy)ethyl-rapamycin, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin, and estradiol.

5. The coating of claim 1, wherein the interpenetrating polymer network is formed from a product selected from the group consisting of poly(ethylene glycol)-acrylate, poly(ethylene glycol)-methacrylate, poly(ethylene glycol)-diacrylate, poly(ethylene glycol)-dimethacrylate, N-vinylpyrrolidone, heparin, and heparin derivatives, hyaluronic acid, derivatives of hyaluronic acid, poly(butyleneterephthalate-co ethylene glycol) (PBT-PEG), and mixtures thereof.

6. The coating of claim 5, wherein the derivatives of heparin comprise heparin salts, heparin containing photoactivatable groups, or heparin containing albumin-binding moieties.

7. The coating of claim 6, wherein the heparin salts are selected from the group consisting of sodium heparin, heparin benzalkonium chloride, heparin tridodecyl methyl ammonium chloride, and mixtures thereof.

8. The coating of claim 6, wherein the photoactivatable groups are derived from benzophenone or dithiocarbonate.

9. The coating of claim 1, wherein the second region is an outermost region of the coating.